Objectives: Sulfonylureas (SU) are a widely prescribed class of oral medications used to treat type 2 diabetes mellitus and are known to cause hypoglycemic events (HE) and weight gain. In this survey, we aimed to identify reasons reported by physicians for discontinuing (DC) or down-titrating (DT) SU therapy.
Introduction
• Diabetes is an increasingly significant public health issue, with the number of individuals diagnosed with diabetes more than doubling over the past three decades 1 • One class of oral antihyperglycemic agents that has been commonly utilized to manage T2DM is sulfonylureas (SUs), which are usually a second-line treatment after maximal benefit has been achieved from first-line medications, but it can also be used as a first-line agent 2 • Across a number of studies, antidiabetic drugs, in particular SUs, have been associated with an increased risk of hypoglycemia 3 and weight gain, which in turn might affect diabetes treatment persistence • The present study sought to understand which factors (including hypoglycemia) affect physicians ' decisions to down-titrate (DT) SU medications or discontinue (DC) them altogether
Objectives
• To identify reasons reported by physicians for discontinuing or down-titrating SU therapy • To examine the demographic profile and patient histories of DC and DT patients relative to current SU users
Methods
Sample and procedure • Patients were recruited through the AllGlobal physician panel -The full panel has 450,000 physicians and healthcare professionals and is double opt-in, that is, one where those who join make a conscious decision to regularly participate in surveys. All panelists are subjected to a stringent verification process to confirm respondents' practicing status. In the US, 100% of panelists are verified as using the American Medical Association (AMA) database • Inclusion criteria required that the physician had at least 2 years of practice, spent at least 50% of their professional time on direct patient care, and was currently treating T2DM patients with SUs (≥10 patients on SU treatment per month) • To ensure adequate representation of physician type, we targeted responses from ~75% primary care physicians (general practice, family practice, or internal medicine) and ~25% specialists (endocrinologists or diabetologists) • Each physician was asked to select and report on 4 patient charts:
-2 charts of patients who are currently on a sulfonylurea (without DT or DC) -1 who has had his or her SU dose down-titrated in the previous 6 months -1 who has had his or her SU discontinued in the previous 6 months • In total, 1,026 physicians completed the study (n = 250, 24.37% specialists) and reported on 4,104 patient charts (DC = 1,026, DT = 1,026, SU = 2,052)
Measures
Physician characteristics -We collected the following information on each physician: gender, age, and SU status of patient population Reasons for discontinuation and down-titration (general) -Physicians were presented with a list of potential reasons why a change in SU therapy might be required and asked the following questions about each reason (this was done separately for discontinuation and down-titration):
• Please rate your level of concern for each reason (1 = not at all concerned, 7 = extremely concerned) (Concern) • Choose the main reasons you personally chose to discontinue [down-titrate] sulfonylurea treatment for T2DM patients in the past (Frequency) • Rate the chosen reasons from most to least important (Importance) Patient characteristics (from charts) -We collected a variety of patient demographic, health, and treatment-specific information from patient charts (see Table 1 for full list) Reasons for discontinuation and down-titration (from charts) -For each individual patient chart, physicians were asked to provide their actual reasons for discontinuing or down-titrating that individual patient's SU treatment Analysis • Descriptive statistics are reported as means and standard deviations for continuous variables and counts and percentages for discrete variables • ANOVAs and Chi-square tests were used to test differences between groups for continuous and categorical variables, respectively. Post-hoc tests for continuous and categorical variables were conducted via Fisher's least significant difference tests and column proportion tests, respectively
Physician survey
• On average, 76% of physicians were male and the majority were between the ages of 35 and 64 (94%) ( Table 1) • Specialists were slightly less likely to be male than PCPs; however, few other differences occurred between these groups with regard to demographics or attitudes, so they are combined for the remaining results ( 
Physician reasons for discontinuation and down-titration (in general)
• When asked about various potential reasons for discontinuation of SUs, physicians cited reasons associated with hypoglycemic events most frequently and rated them with the highest level of concern and importance ( Figure 1A 
Patient charts
• There were a few notable differences between patients with regard to demographics, such that discontinued and down-titrated patients were slightly older than current SU patients. Other differences were small to nonexistent ( Table 2) • Discontinued and down-titrated patients were more likely to have high cholesterol/hyperlipidemia than current SU patients ( • With regard to hypoglycemic events, patients who had been discontinued or down-titrated were significantly more likely to have had ≥1 hypoglycemic event, a higher mean number of hypoglycemic events, and more grade 3 hypoglycemic events in the past 12 months than current SU users ( *Grade 3 events were defined as an event requiring assistance from medical personnel and/or exhibiting marked severity, where "marked severity" is defined as a markedly depressed level of consciousness, loss of consciousness, or seizure.
• There were a few notable differences between physicians' general reasons reported for discontinuation and down-titration relative to actual reasons cited in selected charts. For example, patient preference was more frequently endorsed in patient charts than in general (Figure 2 
Conclusions
• In general, physicians cite hypoglycemic events as important, concerning, and frequent reasons for discontinuing or down-titrating patients' SU treatment. Moreover, few differences were found between PCPs and specialists with regard to these reasons
• Although some differences exist between physicians' general reasons for treatment changes and their actual reasons from patient charts (eg, "patient preference" was more commonly cited in charts than in general reasons), hypoglycemic events remain as commonly cited reasons for discontinuing or down-titrating SUs
• These results are in line with those of patient charts in that patients who have had their SU dose discontinued or down-titrated had more frequent and more severe hypoglycemic events over the past 12 months than current SU users
• Taken together, these results suggest that hypoglycemia is a strong motivating factor in physicians' decisions regarding SU treatment that might affect the overall disease's treatment outcomes
Limitations
• Although the AllGlobal physician panel is designed to be representative of the AMA statistics, our sample may have not been representative of US physicians as a whole
• Physicians were instructed not to use any specific criteria for pulling patient charts in an effort to avoid pulling charts that were nonrepresentative of each patient population as a whole. However, as this was an internet study, there was no way of verifying that these procedures were followed
• This study was cross-sectional and did not follow any patients or physicians longitudinally; thus, certain comparisons and analyses to better understand potential cause and effect could not be conducted
